News | Brachytherapy Systems | January 02, 2018

Prominent cancer centers expand portfolio of patient-centric treatment solutions with Xoft’s painless, scar-free solution

California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer

January 2, 2018 — iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based centers from The US Oncology Network – Santa Clarita Radiation Therapy Center and Sherman Oaks Radiation Therapy Center. Local patients with non-melanoma skin cancer (NMSC), including individuals precluded from surgery or those seeking a non-invasive option, will now have access to a proven alternative.

“We are pleased to provide our community with the most advanced and targeted cancer care that meets the needs of each and every patient,” said May Lin Tao, M.D., medical director of Santa Clarita Radiation Therapy Center.

“Adding Xoft to our infrastructure expands our clinical tools, which help patients achieve similar low rates of recurrence with excellent cosmetic outcomes compared to Mohs surgery – all with virtually no downtime,” said Marc Botnick, M.D., medical director of Sherman Oaks Radiation Therapy Center.

The Xoft technology features a miniaturized, low-energy X-ray source that delivers a precise dose of targeted, isotope-free radiation therapy directly to the lesion, reducing the risk of damage to surrounding healthy tissue. The mobile system can be easily maneuvered from room to room, while minimal shielding requirements enable clinicians to deliver treatment in a standard exam room, offering a highly-efficient, flexible solution.

Appropriate candidates include NMSC patients with lesions in anatomically challenging locations such as the ears, nose, scalp, neck, shin, and elbows, as well as those with wound healing challenges, individuals taking anticoagulants, and patients with medical comorbidities that may prohibit them from surgery.

The Xoft System is cleared by the U.S. Food and Drug Administration (FDA), CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including NMSC, early-stage breast cancer and gynecological cancers.

For more information: www.icadmed.com


Related Content

News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
Subscribe Now